Holen Sie sich die Stockscreener-App
0.9264
0.25%
0.0023
Handel nachbörslich:
.92
-0.0064
-0.69%
Schlusskurs vom Vortag:
$0.9241
Offen:
$0.91
24-Stunden-Volumen:
3.46M
Relative Volume:
0.78
Marktkapitalisierung:
$330.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-63.08M
KGV:
-3.4311
EPS:
-0.27
Netto-Cashflow:
$-72.53M
1W Leistung:
-10.92%
1M Leistung:
+10.65%
6M Leistung:
+2.93%
1J Leistung:
-42.46%
1-Tages-Spanne:
$0.9029
$0.9347
1-Wochen-Bereich:
$0.9029
$1.09
52-Wochen-Spanne:
$0.515
$1.979
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Vergleichen Sie OCGN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
0.9264 | 330.00M | 0 | -63.08M | -72.53M | -0.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha
FDA clears Ocugen’s IND amendment for trial of Stargardt disease treatment - Yahoo Finance
Ocugen to Release New Investor Presentation - TipRanks
Ocugen gets FDA clearance to begin mid-stage study of OCU410ST - MSN
OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy - GuruFocus
Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga
Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha
Ocugen’s IND amendment to begin phase 2/3 confirmatory trial of OCU410ST cleared by FDA - Ophthalmology Times
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen
Ocugen Gets FDA Clearance to Start Phase 2/3 Stargardt Disease Trial - MarketScreener
Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial - GuruFocus
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New - GuruFocus
FDA clears Ocugen’s phase 2/3 trial for Stargardt disease therapy - Investing.com
Ocugen to Showcase Gene Therapy Advancements at 2025 BIO International Convention - MSN
Ocugen To Present at BIO International Convention 2025 | OCGN St - GuruFocus
Ocugen To Present at BIO International Convention 2025 - Ocugen
Ocugen To Present at BIO International Convention 2025 | OCGN Stock News - GuruFocus
Ocugen, Inc. to Present at 2025 BIO International Convention, Showcasing Gene Therapy Advancements for Blindness Diseases - Nasdaq
Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan
Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy - MSN
Ocugen Secures Licensing Agreement for OCU400 in Korea - MSN
Ocugen signs license deal with Korean company for gene therapy - MSN
Ocugen, Inc. (NASDAQ:OCGN) Position Boosted by Wellington Management Group LLP - Defense World
Ameriprise Financial Inc. Invests $30,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen Signs License Agreement for OCU400 in Korea - TipRanks
Ocugen signs term sheet for korean licensing of OCU400 gene therapy - Ophthalmology Times
Ocugen stock rises on Korean licensing deal for gene therapy By Investing.com - Investing.com Nigeria
Ocugen stock rises on Korean licensing deal for gene therapy - Investing.com Australia
Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea - GuruFocus
Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha
BNP Paribas Financial Markets Acquires Shares of 36,859 Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of Ocu400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - MarketScreener
Ocugen inks $11 million gene therapy deal for Korean market - Investing.com Australia
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen
Ocugen Signs Deal for Korean Rights to Gene Therapy OCU400 - marketscreener.com
Ocugen inks $11 million gene therapy deal for Korean market By Investing.com - Investing.com Canada
Ocugen announcing signing of term sheet, enter licensing agreement for OCU400 - TipRanks
Ocugen, Inc. Announces Signing Of Binding Term Sheet For The License Of Ocu400 Modifier Gene Therapy For Retinitis Pigmentosa In Korea - marketscreener.com
Ocugen, Inc. Announces Signing of Binding Term Sheet for the Lic - GuruFocus
Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News - GuruFocus
Ocugen, Inc. Announces Signing of Binding Term Sheet for - GlobeNewswire
Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene ... - Bluefield Daily Telegraph
OCGNOcugen Provides Business Update with First Quarter 2025 Financial Results - Revista ADVFN
Ocugen, Inc. (NASDAQ:OCGN) Stock Position Raised by ProShare Advisors LLC - Defense World
Malvern-Based Ocugen to Pursue Rare Pediatric Disease Therapy - VISTA.Today
Ocugen to Showcase Gene Therapy Advances at Upcoming Ophthalmology Conferences - MSN
Ocugen Receives Rare Pediatric Disease Designation for OCU410ST - MSN
FDA awards Ocugen drug with Rare Pediatric Disease Designation - Pennsylvania Business Report -
Ocugen’s Gene Therapy OCU410ST Nets Rare Pediatric Disease Designation for ABCA4-Associated Retinopathies - CGTLive®
Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment - MSN
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ocugen Inc-Aktie (OCGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fernandes Prabhavathi | Director |
Nov 26 '24 |
Buy |
0.91 |
10,000 |
9,095 |
10,000 |
| Castillo Kirsten | Director |
Nov 22 '24 |
Buy |
0.91 |
25,000 |
22,848 |
75,000 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):